Abstract
Multiple myeloma (MM) is a clonal B cell malignant disease that is characterized by the proliferation of plasma cells in the bone marrow, leading to bone destruction, hematopoietic failure and producing M protein. In recent years, the remission rate and survival of MM patients have been significantly improved with the application of new drugs. But most patients still experience relapse, progression or drug resistance. It′s urgent to seek new treatment strategies of MM. Chimeric antigen receptor-modified T cell (CAR-T) immunotherapy is one of the important biotherapy techniques in the field of tumor immunotherapy in recent years. CAR-T can kill MM cells by specifically identifying target antigens and provide new therapy for patients with MM. This article intends to expound the relevant targets, existing problems and the measures to improve the effectiveness of CAR-T in treatment of MM. Key words: Multiple myeloma; Immunotherapy, adoptive; Molecular targeted therapy; Clinical protocols; Chimeric antigen receptor T cell immunotherapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
